531 related articles for article (PubMed ID: 15683427)
1. Iron overload in patients with chronic hepatitis C virus infection: clinical and histological study.
Silva IS; Perez RM; Oliveira PV; Cantagalo MI; Dantas E; Sisti C; Figueiredo-Mendes C; Lanzoni VP; Silva A; Ferraz ML
J Gastroenterol Hepatol; 2005 Feb; 20(2):243-8. PubMed ID: 15683427
[TBL] [Abstract][Full Text] [Related]
2. Hepatic iron, liver steatosis and viral genotypes in patients with chronic hepatitis C.
Sebastiani G; Vario A; Ferrari A; Pistis R; Noventa F; Alberti A
J Viral Hepat; 2006 Mar; 13(3):199-205. PubMed ID: 16475996
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of iron status in patients with chronic hepatitis C.
Sartori M; Andorno S; La Terra G; Boldorini R; Leone F; Pittau S; Zecchina G; Aglietta M; Saglio G
Ital J Gastroenterol Hepatol; 1998 Aug; 30(4):396-401. PubMed ID: 9789136
[TBL] [Abstract][Full Text] [Related]
4. Hepatic iron overload does not prevent a sustained virological response to interferon-alpha therapy: a long term follow-up study in hepatitis C-infected patients with beta thalassemia major.
Sievert W; Pianko S; Warner S; Bowden S; Simpson I; Bowden D; Locarnini S
Am J Gastroenterol; 2002 Apr; 97(4):982-7. PubMed ID: 12003436
[TBL] [Abstract][Full Text] [Related]
5. Relationship between serum ferritin, hepatic iron staining, diabetes mellitus and fibrosis progression in patients with chronic hepatitis C.
D'Souza RF; Feakins R; Mears L; Sabin CA; Foster GR
Aliment Pharmacol Ther; 2005 Mar; 21(5):519-24. PubMed ID: 15740534
[TBL] [Abstract][Full Text] [Related]
6. Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C.
Hofer H; Osterreicher C; Jessner W; Penz M; Steindl-Munda P; Wrba F; Ferenci P
J Hepatol; 2004 Jun; 40(6):1018-22. PubMed ID: 15158344
[TBL] [Abstract][Full Text] [Related]
7. Hemochromatosis gene mutations in chronic hepatitis C patients with and without liver siderosis.
Negro F; Samii K; Rubbia-Brandt L; Quadri R; Male PJ; Zarski JP; Baud M; Giostra E; Beris P; Hadengue A
J Med Virol; 2000 Jan; 60(1):21-7. PubMed ID: 10568758
[TBL] [Abstract][Full Text] [Related]
8. Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C.
Di Marco V; Capra M; Gagliardotto F; Borsellino Z; Cabibi D; Barbaria F; Ferraro D; Cuccia L; Ruffo GB; Bronte F; Di Stefano R; Almasio PL; Craxì A
Haematologica; 2008 Aug; 93(8):1243-6. PubMed ID: 18556410
[TBL] [Abstract][Full Text] [Related]
9. Hepatic iron overload in children with sickle cell anemia on chronic transfusion therapy.
Brown K; Subramony C; May W; Megason G; Liu H; Bishop P; Walker T; Nowicki MJ
J Pediatr Hematol Oncol; 2009 May; 31(5):309-12. PubMed ID: 19415007
[TBL] [Abstract][Full Text] [Related]
10. Iron overload in patients with chronic viral hepatitis: how common is it?
Riggio O; Montagnese F; Fiore P; Folino S; Giambartolomei S; Gandin C; Merli M; Quinti I; Violante N; Caroli S; Senofonte O; Capocaccia L
Am J Gastroenterol; 1997 Aug; 92(8):1298-1301. PubMed ID: 9260793
[TBL] [Abstract][Full Text] [Related]
11. [Aspartate aminotransferase (AST) more than alanine aminotransferase (ALT) levels predict the progression of liver fibrosis in chronic HCV infection].
Stránský J; Ryzlová M; Striteský J; Horák J
Vnitr Lek; 2002 Oct; 48(10):924-8. PubMed ID: 16737138
[TBL] [Abstract][Full Text] [Related]
12. Is alanine aminotransferase a good marker of histologic hepatic damage in renal transplant patients with hepatitis C virus infection?
Perez RM; Ferreira AS; Medina-Pestana JO; Lanzoni VP; Silva AE; Ferraz ML
Clin Transplant; 2005 Oct; 19(5):622-5. PubMed ID: 16146553
[TBL] [Abstract][Full Text] [Related]
13. Effects of iron loading on pathogenicity in hepatitis C virus-infected chimpanzees.
Bassett SE; Di Bisceglie AM; Bacon BR; Sharp RM; Govindarajan S; Hubbard GB; Brasky KM; Lanford RE
Hepatology; 1999 Jun; 29(6):1884-92. PubMed ID: 10347134
[TBL] [Abstract][Full Text] [Related]
14. Hepatic oxidative DNA damage correlates with iron overload in chronic hepatitis C patients.
Fujita N; Horiike S; Sugimoto R; Tanaka H; Iwasa M; Kobayashi Y; Hasegawa K; Ma N; Kawanishi S; Adachi Y; Kaito M
Free Radic Biol Med; 2007 Feb; 42(3):353-62. PubMed ID: 17210448
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C among predialysis patients: prevalence and characteristics in a large cohort of patients.
Lemos LB; Perez RM; Lemos MM; Draibe SA; Silva IS; Silva AE; Ferraz ML
Nephron Clin Pract; 2008; 108(2):c135-40. PubMed ID: 18230916
[TBL] [Abstract][Full Text] [Related]
16. Glucose abnormalities in non-alcoholic fatty liver disease and chronic hepatitis C virus infection: the role of iron overload.
Lecube A; Hernández C; Simó R
Diabetes Metab Res Rev; 2009 Jul; 25(5):403-10. PubMed ID: 19444865
[TBL] [Abstract][Full Text] [Related]
17. Comparative study between occult hepatitis C virus infection and chronic hepatitis C.
Pardo M; López-Alcorocho JM; Rodríguez-Iñigo E; Castillo I; Carreño V
J Viral Hepat; 2007 Jan; 14(1):36-40. PubMed ID: 17212642
[TBL] [Abstract][Full Text] [Related]
18. Steatosis in chronic hepatitis C: relationship to the virus and host risk factors.
Matos CA; Perez RM; Pacheco MS; Figueiredo-Mendes CG; Lopes-Neto E; Oliveira EB; Lanzoni VP; Silva AE; Ferraz ML
J Gastroenterol Hepatol; 2006 Aug; 21(8):1236-9. PubMed ID: 16872303
[TBL] [Abstract][Full Text] [Related]
19. Antinuclear antibody is associated with a more advanced fibrosis and lower RNA levels of hepatitis C virus in patients with chronic hepatitis C.
Hsieh MY; Dai CY; Lee LP; Huang JF; Tsai WC; Hou NJ; Lin ZY; Chen SC; Wang LY; Chang WY; Chuang WL; Yu ML
J Clin Pathol; 2008 Mar; 61(3):333-7. PubMed ID: 17545561
[TBL] [Abstract][Full Text] [Related]
20. Comparison of hepatic oxidative DNA damage in patients with chronic hepatitis B and C.
Fujita N; Sugimoto R; Ma N; Tanaka H; Iwasa M; Kobayashi Y; Kawanishi S; Watanabe S; Kaito M; Takei Y
J Viral Hepat; 2008 Jul; 15(7):498-507. PubMed ID: 18331251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
